Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.76 and traded as low as $2.86. Galmed Pharmaceuticals shares last traded at $2.93, with a volume of 48,546 shares.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on shares of Galmed Pharmaceuticals in a research report on Wednesday, October 9th. They set a “sell” rating on the stock.
Read Our Latest Research Report on GLMD
Galmed Pharmaceuticals Stock Down 0.3 %
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- The Basics of Support and Resistance
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Ride Out The Recession With These Dividend Kings
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
